Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by SABBOBCATon Dec 04, 2019 11:51am
172 Views
Post# 30421208

RE:RE:RE:RE:Taimed Nov sales

RE:RE:RE:RE:Taimed Nov salesThe seller may be a large holder (CDPQ?) or a large number of retail sellers. Given the target price downgrades in the last few months, there may be advisors pr small investors that are not as familiar with the story that are indesceriminently selling at market. This crushes the price and really drives us long term holders CRAZY, but also is an indication that things may change quickly once the tide reverses. There has been significant volumes snapped up at these levels which indicates we may finally be building a base here. January could be quite the show as tax loss season is done and we see market buys out weighing the market sells.
Woolwurth33 wrote: I think that this year long selling is just a smart large investor taking profit after buying low. My theory is they will be done when TH earnings show a steady rise or FDA approval for the trial and will begin buying back in along with other investors and a long slow climb will begin.


Bullboard Posts